Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]
News [3235]
Articles [134]
Editorials [3]
Conferences [122]
elearning [18]
Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma
Dr Sagar Lonial – Emory University, Atlanta, USA
Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma ( Dr Sagar Lonial – Emory University, Atlanta, USA )
15 Jun 2012
Hodgkin Lymphoma focusing on reducing radiotherapy, while maintaining the...
Prof Andreas Engert - University Hospital of Cologne, Germany
Hodgkin Lymphoma focusing on reducing radiotherapy, while maintaining the highest possible cure rate ( Prof Andreas Engert - University Hospital of Cologne, Germany )
13 Jun 2012
ASCO 2012: Advances in myeloma
Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof...
ASCO 2012: Advances in myeloma ( Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Gareth Morgan - Royal Marsden Hospital, UK )
12 Jun 2012
ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma
Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias...
ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rummel - University Hospital Giessen, Germany )
12 Jun 2012
President's overview of ASCO 2012
Dr Michael Link - Stanford School of Medicine, California, USA
President's overview of ASCO 2012 ( Dr Michael Link - Stanford School of Medicine, California, USA )
4 Jun 2012
Changing the standard treatment for lymphoma with bendamustine
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Changing the standard treatment for lymphoma with bendamustine ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
3 Jun 2012
Bendamustine regimen more effective for lymphoma than standard CHOP
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Bendamustine regimen more effective for lymphoma than standard CHOP ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
3 Jun 2012
Relapse and survival of adolescent and young adult leukaemia patients
Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA
Relapse and survival of adolescent and young adult leukaemia patients ( Dr Eric Larsen - Maine Children’s Cancer Program, Scarborough, USA )
2 Jun 2012
Ibrutinib induces responses in aggressive lymphomas
Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA
Ibrutinib induces responses in aggressive lymphomas ( Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA )
13 Apr 2012
Recent advances in multiple myeloma therapy
Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios...
Recent advances in multiple myeloma therapy ( Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimopoulos and Prof Thierry Facon )
14 Feb 2012
Recent advances in non-Hodgkin’s lymphoma therapy
Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter
Recent advances in non-Hodgkin’s lymphoma therapy ( Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter )
14 Feb 2012
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory...
Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston )
9 Jan 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation